Clinical Trials Browser

Phase 2 × Prostatic Neoplasms × tislelizumab × Clear all

NCT05189457 2025-12-04

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms